Incyte Corporation vs Rush Street Interactive Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Rush Street Interactive Inc trades at $18.9 (market cap $2.35B). The key difference: Incyte Corporation is far larger — about 9.7× Rush Street Interactive Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Rush Street Interactive Inc for 13 Days on average.
| INCY | RSI | |
|---|---|---|
Market Cap | $22.85B | $2.35B |
Volume | 1,927,029 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $34.52 |
52-Week Low | $83.80 | $15.89 |
Typical Hold Time | 33 Days | 13 Days |
Enterprise Value | $18.35B | $2.01B |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Rush Street Interactive (RSI) trades at $20.32, up 0.4% on the day, with a bearish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and revenue growth from $1.13B in 2025 to $1.4B in 2026. Analyst consensus is bullish with a $34.88 price target, though net income margin compression from 2.93% to 2.33% highlights profitability challenges.
RSI presents a mixed outlook: robust revenue growth and solid analyst support contrast with thin margins and bearish technicals. The stock offers upside to consensus targets but faces execution risks in a competitive online betting market. Investors should weigh growth potential against margin pressures and market sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →